{"id":2739,"date":"2025-03-18T11:52:11","date_gmt":"2025-03-18T11:52:11","guid":{"rendered":"https:\/\/genosophy.gr\/product\/klironomikoi-karkinoi-2\/"},"modified":"2025-04-24T13:22:09","modified_gmt":"2025-04-24T13:22:09","slug":"klironomikoi-karkinoi-2","status":"publish","type":"product","link":"https:\/\/genosophy.gr\/en\/product\/klironomikoi-karkinoi-2\/","title":{"rendered":"Hereditary Cancers"},"content":{"rendered":"

Hereditary cancer syndromes account for 5\u201310% of all cancer cases<\/strong>, primarily affecting the gastrointestinal<\/strong>, endocrine<\/strong>, and neuroendocrine systems<\/strong>, as well as organs such as the pancreas<\/strong>, kidneys<\/strong>, liver<\/strong>, skin<\/strong>, and eyes<\/strong>.<\/p>\n

The GENOSOPHY\u00ae Comprehensive Hereditary Cancer Panel<\/strong> analyzes 162 genes<\/strong>, offering advanced genetic investigation for a wide range of inherited cancer syndromes.<\/p>\n

Conditions Covered by the Genetic Test<\/h3>\n

The panel includes disorders such as:<\/p>\n

    \n
  • Hereditary Colorectal Cancer & Lynch Syndrome<\/strong><\/li>\n
  • Hereditary Breast and Ovarian Cancer (HBOC Syndrome)<\/strong><\/li>\n
  • Familial Pancreatic Cancer<\/strong> (BRCA2, CDKN2A, PALB2)<\/li>\n
  • Hereditary Prostate Cancer<\/strong> (BRCA2, HOXB13)<\/li>\n
  • Li-Fraumeni Syndrome<\/strong> (TP53)<\/li>\n
  • Peutz-Jeghers Syndrome<\/strong> (STK11)<\/li>\n
  • Von Hippel\u2013Lindau Syndrome<\/strong> (VHL)<\/li>\n<\/ul>\n

    Clinical Benefits<\/h3>\n

    Diagnosis<\/h4>\n
      \n
    • Identification of pathogenic variants<\/strong> linked to increased cancer risk<\/li>\n
    • Differentiation between sporadic and hereditary<\/strong> cancer forms<\/li>\n<\/ul>\n

      Prognosis<\/h4>\n
        \n
      • Assessment of personal and familial cancer risk<\/strong><\/li>\n
      • Guidance for preventive monitoring and therapeutic strategies<\/strong><\/li>\n<\/ul>\n

        Management<\/h4>\n
          \n
        • Personalized recommendations for monitoring and prevention<\/strong><\/li>\n
        • Decision-making on enhanced surveillance or prophylactic surgery<\/strong><\/li>\n
        • Therapeutic planning (e.g. PARP inhibitors<\/strong> for BRCA carriers)<\/li>\n<\/ul>\n

          Testing Procedure<\/h4>\n
            \n
          1. Sample collection<\/strong> (blood or saliva)<\/li>\n
          2. Analysis of 162 genes<\/strong> associated with hereditary cancer syndromes using Next-Generation Sequencing (NGS)<\/strong><\/li>\n
          3. Results available in 5\u20136 weeks<\/strong><\/li>\n<\/ol>\n

            Additional genetic counseling and result interpretation<\/strong> is available by Professors of the National and Kapodistrian University of Athens (EKPA)<\/strong> as a separate service.<\/p>\n

            Genes Included in the Panel<\/h3>\n

            AIP, ALK, ANKRD26, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A*, BRAF, BRCA1, BRCA2, BRIP1, BUB1B, CBL, CD70, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEP57, CHEK2*, CPA1, CTNNA1, CYLD, DDB2, DDX41, DICER1*, DIS3L2*, DKC1, EFL1*, EGFR, ELANE, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EXO1, EZH2, FAM111B*, FANCA, FANCB, FANCC, FANCD2*, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GALNT12, GATA2, GPC3, GPR101, GREM1, HAVCR2, HNF1A, HOXB13, HRAS, IKZF1, KIT, KITLG, KRAS*, LZTR1, MAP2K1, MAP2K2, MAP3K1, MAX, MEN1, MET, MITF, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1*, NF2, NRAS, NSD1, NSUN2, NTHL1, PALB2, PAX5, PDGFRA#, PHOX2B, PMS1, PMS2*, POLD1, POLE, POLH*, POT1, PPM1D, PRF1, PRKAR1A, PTCH1, PTEN*, PTPN11, RAD50, RAD51C, RAD51D, RAF1, RASA2, RB1, RECQL*, RECQL4, REST, RET, RHBDF2, RIT1, RRAS, RUNX1, SAMD9, SAMD9L, SBDS*, SDHA*, SDHAF2, SDHB, SDHC, SDHD*, SHOC2, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SOS2, SPRED1, SRP72*, STK11, SUFU, TERC, TERT, TINF2, TMEM127, TP53, TRIP13, TSC1, TSC2, VHL, WRN*, WT1, XPA, XPC, XRCC2<\/strong><\/p>\n

            Note:<\/strong> In addition to all exons, the GENOSOPHY\u00ae test analyzes non-coding variants<\/strong> (e.g. promoters and introns) that may provide clinically useful information.
            \nThe detection sensitivity<\/strong> for SNVs, indels, and CNVs<\/strong> is >99%<\/strong>, with slightly lower sensitivity for genes marked with an asterisk (*).<\/p>\n","protected":false},"excerpt":{"rendered":"

            Hereditary cancer syndromes account for 5\u201310% of all cancer cases, primarily affecting the gastrointestinal, endocrine, and neuroendocrine systems, as well as organs such as the pancreas, kidneys, liver, skin, and eyes. The GENOSOPHY\u00ae Comprehensive Hereditary Cancer Panel analyzes 162 genes, offering advanced genetic investigation for a wide range of inherited cancer syndromes. Conditions Covered by […]<\/p>\n","protected":false},"featured_media":2462,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[85],"product_tag":[],"class_list":{"0":"post-2739","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-oncologic-ipiresies-gia-epaggelmaties-en","8":"first","9":"instock","10":"taxable","11":"shipping-taxable","12":"product-type-simple"},"acf":[],"_links":{"self":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product\/2739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media\/2462"}],"wp:attachment":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media?parent=2739"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_brand?post=2739"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_cat?post=2739"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_tag?post=2739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}